ABSTRACT
The bioequivalence (BE) review process establishes that the proposed generic drug is bioequivalent to the reference listed drug, based upon a demonstration that both the rate and extent of absorption of the active ingredient of the generic drug fall within established parameters when compared to that of the reference listed drug.
